IL-17A has recently emerged as a protective cytokine for inflammatory bowel diseases, as a result of which clinical trials with secukinumab or brodalumab in patients with IBD resulted in enhanced Candida infections and increased intestinal inflammation. The gene discussed is IL17A; the disease is inflammatory bowel disease.